clinical trial · NCT06537999
A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy
Multifocal Motor NeuropathyDNTH103Placebo
brief summary
The purpose of this Phase 2 study is to evaluate the safety, tolerability, pharmacometrics, and efficacy of DNTH103 in participants with multifocal motor neuropathy (MMN).
started
Sep 17, 2024
primary completion
Jun 30, 2026
completion
Mar 31, 2028
last updated
Oct 6, 2025
official title
A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Study to Evaluate Safety, Tolerability, Pharmacometrics, and Efficacy of DNTH103 in Adults With Multifocal Motor Neuropathy (MOMENTUM)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol